NASDAQ:AGIO - Agios Pharmaceuticals Stock Price, Price Target & More

$86.45 -1.84 (-2.08 %)

(As of 04/22/2018 04:00 PM ET)

Previous Close$86.45

Today's Range$85.65 - $88.3010

52-Week Range$45.11 - $89.33

Volume572,722 shs

Average Volume409,864 shs

Market Capitalization$4.96 billion

P/E Ratio-12.81

Dividend YieldN/A

Beta1.98

About Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML. The company also develops Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase I clinical trial for advanced solid tumors; Phase III clinical trials for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination and Phase III clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase I clinical trial for the treatment of hematologic malignancies; and AG-348, a small molecule potent activator that is in Phase II clinical trials for the treatment of pyruvate kinase deficiency. Agios Pharmaceuticals has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is based in Cambridge, Massachusetts.

Receive AGIO News and Ratings via Email

Sign-up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:AGIO

CUSIPN/A

Webwww.agios.com

Phone617-649-8600

Debt

Debt-to-Equity RatioN/A

Current Ratio4.69%

Quick Ratio4.69%

Price-To-Earnings

Trailing P/E Ratio-12.81

Forward P/E Ratio-13.83

P/E GrowthN/A

Sales & Book Value

Annual Sales$43.01 million

Price / Sales115.23

Cash FlowN/A

Price / CashN/A

Book Value$7.69 per share

Price / Book11.24

Profitability

EPS (Most Recent Fiscal Year)($6.75)

Net Income$-314,670,000.00

Net Margins-731.60%

Return on Equity-76.67%

Return on Assets-48.05%

Miscellaneous

Employees382

Outstanding Shares57,330,000

How to Become a New Pot Stock Millionaire

Agios Pharmaceuticals (NASDAQ:AGIO) Frequently Asked Questions

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals (NASDAQ:AGIO) issued its quarterly earnings results on Wednesday, February, 14th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.65) by $0.16. The biopharmaceutical company had revenue of $9.80 million for the quarter, compared to analysts' expectations of $12.65 million. Agios Pharmaceuticals had a negative return on equity of 76.67% and a negative net margin of 731.60%. The company's revenue was down 56.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.34) EPS. View Agios Pharmaceuticals' Earnings History.

When is Agios Pharmaceuticals' next earnings date?

Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, May, 4th 2018. View Earnings Estimates for Agios Pharmaceuticals.

What price target have analysts set for AGIO?

11 brokers have issued 1-year price objectives for Agios Pharmaceuticals' stock. Their predictions range from $75.00 to $101.00. On average, they anticipate Agios Pharmaceuticals' stock price to reach $87.3333 in the next twelve months. View Analyst Ratings for Agios Pharmaceuticals.

What are Wall Street analysts saying about Agios Pharmaceuticals stock?

Here are some recent quotes from research analysts about Agios Pharmaceuticals stock:

1. Cann analysts commented, "While we have not modeled any revenue impact from AG-270 to either Agios or Celgene by 2022, we believe that AG-270 could be an important value driver for Agios and Celgene. AG-270 is a novel compound in the field of synthetic lethality, and has the potential to address large patient populations. We are not making any changes to our outlook at this time, but we continue to watch the timing of the program closely." (4/17/2018)
2. According to Zacks Investment Research, "Agios received an FDA approval of Idhifa (enasidenib) in August for treatment of AML, which was a huge boost, given the immense commercial potential in the target market. We are also optimistic about its collaboration with Celgene as it provides Agios with regular funds. The company’s progress with the pipeline candidates, AG-120 and AG-881, has been quite impressive too. In December, the company submitted a new drug application to the FDA for AG-120 for treatment of AML. Shares of the company have outperformed the industry in the last one year. However, Agios depends heavily on partner Celgene for revenues as Idhifa is only in the early stages of launch. Also, the decision to discontinue the development of AG-519 was disappointing. Stiff competition is another matter of concern for the company." (1/16/2018)

Who are some of Agios Pharmaceuticals' key competitors?

Some companies that are related to Agios Pharmaceuticals include Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), BeiGene (BGNE), Alkermes (ALKS), SAGE Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), Valeant Pharmaceuticals International (VRX), Catalent (CTLT), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Gal�pagos (GLPG), United Therapeutics (UTHR), Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN), GW Pharmaceuticals (GWPH) and Advanced Accelerator Application (AAAP).

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the folowing people:

Dr. David P. Schenkein M.D., CEO, Pres & Director (Age 61)
Dr. Lewis Clayton Cantley, Co-Founder & Member of Scientific Advisory Board (Age 69)
Mr. Andrew Hirsch, Chief Financial Officer (Age 47)
Dr. Scott A. Biller Ph.D., Chief Scientific Officer (Age 62)
Dr. Christopher Bowden, Chief Medical Officer (Age 57)

Has Agios Pharmaceuticals been receiving favorable news coverage?

News headlines about AGIO stock have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Agios Pharmaceuticals earned a news impact score of 0.11 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 46.18 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Agios Pharmaceuticals' major shareholders?

Agios Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include CELGENE EUROPEAN INVESTMENT COMPANY LLC (12.10%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Celgene European Investment Co, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, David Scadden, Kaye I Foster-Cheek, Lewis Clayton Jr Cantley, Robert Nelsen, Scott Biller and Steven L Hoerter. View Institutional Ownership Trends for Agios Pharmaceuticals.

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Agios Pharmaceuticals' stock price today?

One share of AGIO stock can currently be purchased for approximately $86.45.

How big of a company is Agios Pharmaceuticals?

Agios Pharmaceuticals has a market capitalization of $4.96 billion and generates $43.01 million in revenue each year. The biopharmaceutical company earns $-314,670,000.00 in net income (profit) each year or ($6.75) on an earnings per share basis. Agios Pharmaceuticals employs 382 workers across the globe.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]

MarketBeat Community Rating for Agios Pharmaceuticals (AGIO)

Community Ranking:		2.6 out of 5 ( )
Outperform Votes:		268 (Vote Outperform)
Underperform Votes:		252 (Vote Underperform)
Total Votes:		520

MarketBeat's community ratings are surveys of what our community members think about Agios Pharmaceuticals and other stocks. Vote "Outperform" if you believe AGIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGIO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Agios Pharmaceuticals (NASDAQ:AGIO) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

11 Wall Street analysts have issued ratings and price targets for Agios Pharmaceuticals in the last 12 months. Their average twelve-month price target is $87.3333, suggesting that the stock has a possible upside of 1.02%. The high price target for AGIO is $101.00 and the low price target for AGIO is $75.00. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.64	2.73	2.91	2.92
Ratings Breakdown:	0 Sell Rating(s) 4 Hold Rating(s) 7 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 3 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$87.3333	$85.6667	$77.00	$75.20
Price Target Upside:	1.02% upside	9.87% upside	9.48% upside	8.53% upside

Agios Pharmaceuticals (NASDAQ:AGIO) Consensus Price Target History

Price Target History for Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ:AGIO) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/17/2018	Cann	Reiterated Rating	Hold		Low
4/11/2018	Credit Suisse Group	Set Price Target	Outperform -> Buy	$80.00 -> $95.00	Medium
2/15/2018	SunTrust Banks	Reiterated Rating	Buy -> Buy	$80.00 -> $101.00	Low
2/15/2018	JPMorgan Chase	Boost Price Target	Overweight -> Overweight	$76.00 -> $85.00	Low
2/15/2018	Needham & Company LLC	Boost Price Target	Buy -> Buy	$72.00 -> $86.00	Low
2/14/2018	Oppenheimer	Downgrade	Outperform -> Market Perform		Low
2/14/2018	UBS	Downgrade	Outperform -> Market Perform		Low
1/18/2018	Royal Bank of Canada	Boost Price Target	Outperform	$91.00	Medium
12/12/2017	Canaccord Genuity	Set Price Target	Buy	$90.00	High
8/2/2017	Leerink Swann	Upgrade	Market Perform -> Outperform	$50.00 -> $80.00	High
8/1/2017	Janney Montgomery Scott	Reiterated Rating	Hold		High
2/16/2017	Cowen	Reiterated Rating	Buy		N/A
1/17/2017	CIBC	Upgrade	Market Perform -> Outperform		N/A
8/19/2016	BTIG Research	Initiated Coverage	Neutral		N/A
8/10/2016	Goldman Sachs	Reiterated Rating	Neutral	$46.00	N/A

(Data available from 4/22/2016 forward)

Agios Pharmaceuticals (NASDAQ:AGIO) Earnings History and Estimates Chart

Earnings by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ:AGIO) Earnings Estimates

2018 EPS Consensus Estimate: ($5.97)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	3	($1.65)	($1.57)	($1.61)
Q2 2018	3	($1.63)	($1.44)	($1.55)
Q3 2018	3	($1.89)	($1.42)	($1.66)
Q4 2018	3	($1.53)	($0.58)	($1.15)

Agios Pharmaceuticals (NASDAQ AGIO) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/2/2018		($1.68)					N/A
2/14/2018	Q4 2017	($1.65)	($1.81)	$12.65 million	$9.80 million	View	Listen
11/1/2017	Q3 2017	($1.78)	($1.59)	$10.85 million	$11.35 million	View	N/A
8/8/2017	Q2 2017	($1.57)	($1.78)	$10.68 million	$11.30 million	View	Listen
5/4/2017	Q1 2017	($1.80)	($1.56)	$9.65 million	$10.51 million	View	Listen
2/16/2017	Q416	($1.51)	($1.34)	$10.89 million	$22.65 million	View	Listen
11/3/2016	Q316	($1.52)	($1.63)	$7.82 million	$8.98 million	View	Listen
8/4/2016	Q216	($0.48)	($1.47)	$39.62 million	$6.98 million	View	Listen
5/5/2016	Q116	($0.79)	($0.61)	$20.94 million	$31.30 million	View	Listen
2/18/2016	Q415	($0.27)	($1.08)	$28.78 million	$6.22 million	View	Listen
11/5/2015	Q315	($0.89)	($1.07)	$17.21 million	$5.80 million	View	Listen
8/6/2015	Q215	($0.46)	($0.85)	$25.75 million	$13.20 million	View	Listen
5/7/2015	Q115	($0.86)	($0.13)	$10.86 million	$34.20 million	View	Listen
2/17/2015	Q414	($0.55)	($0.76)	$10.94 million	$14.64 million	View	Listen
11/7/2014	Q314	($0.53)	$0.10	$8.45 million	$33.90 million	View	Listen
8/7/2014	Q2	($0.47)	($0.54)	$11.00 million	$8.41 million	View	Listen
5/8/2014	Q1	($0.37)	($0.39)	$7.19 million	$8.41 million	View	Listen
3/6/2014	Q4	($0.34)	($0.40)	$6.19 million	$6.70 million	View	Listen
11/7/2013		($0.28)	($0.47)	$6.22 million	$6.27 million	View	Listen
9/5/2013	Q2 2013	($0.28)	($2.80)	$6.19 million	$6.27 million	View	N/A

(Earnings results data provided by Zacks Investment Research)

Agios Pharmaceuticals (NASDAQ:AGIO) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Agios Pharmaceuticals (NASDAQ AGIO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.43%
Institutional Ownership Percentage: 82.41%

Insider Trading History for Agios Pharmaceuticals (NASDAQ:AGIO)

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ AGIO) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/12/2018	Christopher Bowden	Insider	Sell	2,000	$85.10	$170,200.00	2,881
4/5/2018	Scott Biller	Insider	Sell	3,000	$75.20	$225,600.00	60,196
4/2/2018	David P Schenkein	CEO	Sell	13,000	$77.72	$1,010,360.00
3/22/2018	Steven L Hoerter	Insider	Sell	2,050	$84.65	$173,532.50	2,050
3/19/2018	Kaye I Foster-Cheek	Director	Sell	6,800	$81.97	$557,396.00	9,000
3/16/2018	David Scadden	Director	Buy	200	$83.44	$16,688.00	571
3/5/2018	Scott Biller	Insider	Sell	3,000	$83.08	$249,240.00
3/1/2018	David P Schenkein	CEO	Sell	13,000	$81.09	$1,054,170.00
2/22/2018	Steven L Hoerter	Insider	Sell	2,050	$78.63	$161,191.50	2,050
2/16/2018	Christopher Bowden	Insider	Sell	2,000	$77.65	$155,300.00
2/5/2018	Scott Biller	Insider	Sell	3,000	$76.04	$228,120.00
2/1/2018	Christopher Bowden	Insider	Sell	2,000	$78.75	$157,500.00	2,881
2/1/2018	David P Schenkein	CEO	Sell	13,000	$78.75	$1,023,750.00	13,000
1/26/2018	David P Schenkein	CEO	Sell	23,572	$81.09	$1,911,453.48	23,572
1/24/2018	David P Schenkein	CEO	Sell	46,408	$80.01	$3,713,104.08	32,875
1/23/2018	Corp /De/ Celgene	Major Shareholder	Buy	851,154	$67.00	$57,027,318.00	1,374,599
1/23/2018	Steven L Hoerter	Insider	Sell	25,000	$74.83	$1,870,750.00	25,000
1/16/2018	David P Schenkein	CEO	Sell	53,000	$73.16	$3,877,480.00	53,000
1/12/2018	Carman Alenson	Insider	Sell	2,150	$75.00	$161,250.00	2,150
1/10/2018	Scott Biller	Insider	Sell	3,000	$65.00	$195,000.00	56,059
12/7/2017	Lewis Clayton Jr. Cantley	Director	Sell	3,838	$59.37	$227,862.06	80,851
12/1/2017	David P Schenkein	CEO	Sell	6,000	$61.55	$369,300.00	6,000
12/1/2017	Scott Biller	Insider	Sell	2,146	$60.79	$130,455.34	8,410
11/14/2017	Lewis Clayton Jr. Cantley	Director	Sell	4,000	$60.88	$243,520.00	82,394
11/1/2017	David P Schenkein	CEO	Sell	6,000	$63.85	$383,100.00
11/1/2017	Scott Biller	Insider	Sell	2,146	$62.69	$134,532.74
10/17/2017	Lewis Clayton Jr. Cantley	Director	Sell	4,000	$71.10	$284,400.00	84,394
10/16/2017	Lewis Clayton Jr. Cantley	Director	Sell	1,000	$71.09	$71,090.00	84,394
10/4/2017	David P Schenkein	CEO	Sell	80,000	$70.14	$5,611,200.00
10/4/2017	Scott Biller	Insider	Sell	10,470	$70.00	$732,900.00
10/2/2017	David P Schenkein	CEO	Sell	6,000	$66.76	$400,560.00
10/2/2017	Scott Biller	Insider	Sell	2,146	$67.23	$144,275.58
9/18/2017	David P Schenkein	CEO	Sell	35,000	$67.12	$2,349,200.00	35,000
9/14/2017	Lewis Clayton Jr. Cantley	Director	Sell	4,000	$65.59	$262,360.00	86,394
9/13/2017	Lewis Clayton Jr. Cantley	Director	Sell	1,000	$65.47	$65,470.00	86,394
9/11/2017	Scott Biller	Insider	Sell	15,000	$65.00	$975,000.00	6,264
9/1/2017	David P Schenkein	CEO	Sell	6,000	$62.20	$373,200.00	6,000
9/1/2017	Scott Biller	Insider	Sell	2,146	$61.99	$133,030.54	8,410
8/23/2017	Lewis Clayton Jr. Cantley	Director	Sell	4,000	$56.85	$227,400.00
8/2/2017	David P Schenkein	CEO	Sell	27,000	$59.95	$1,618,650.00	3,000
8/2/2017	Scott Biller	Insider	Sell	23,146	$59.60	$1,379,501.60	8,410
7/20/2017	Lewis Clayton Jr. Cantley	Director	Sell	9,000	$56.36	$507,240.00	86,697
7/19/2017	Lewis Clayton Jr. Cantley	Director	Sell	3,500	$56.14	$196,490.00	86,697
7/7/2017	Scott Biller	Insider	Sell	2,146	$55.00	$118,030.00	8,410
7/3/2017	David P Schenkein	CEO	Sell	3,000	$51.18	$153,540.00	3,000
6/21/2017	Scott Biller	Insider	Sell	4,292	$55.00	$236,060.00
6/14/2017	Lewis Clayton Jr. Cantley	Director	Sell	2,000	$50.87	$101,740.00	90,197
6/7/2017	David P Schenkein	CEO	Sell	3,000	$50.02	$150,060.00	1,100
5/25/2017	Lewis Clayton Jr. Cantley	Director	Sell	2,036	$47.10	$95,895.60	91,206
5/1/2017	David P Schenkein	CEO	Sell	3,000	$50.06	$150,180.00	3,000
4/24/2017	Celgene European Investment Co	Major Shareholder	Buy	624,575	$49.50	$30,916,462.50
4/18/2017	Lewis Clayton Jr. Cantley	Director	Sell	5,090	$54.37	$276,743.30	93,751
4/17/2017	Lewis Clayton Jr. Cantley	Director	Sell	2,036	$55.24	$112,468.64	93,751
4/3/2017	David P Schenkein	CEO	Sell	3,000	$58.62	$175,860.00	3,000
4/3/2017	Scott Biller	Insider	Sell	2,146	$58.03	$124,532.38
3/23/2017	Lewis Clayton Jr. Cantley	Director	Sell	2,036	$53.11	$108,131.96	94,769
3/20/2017	Scott Biller	Insider	Sell	6,438	$55.00	$354,090.00	21,403
3/6/2017	Robert Nelsen	Director	Sell	40,599	$50.84	$2,064,053.16	109,230
2/28/2017	Robert Nelsen	Director	Sell	243,082	$49.36	$11,998,527.52	109,230
2/23/2017	Robert Nelsen	Director	Sell	135,364	$49.37	$6,682,920.68	73,078
2/16/2017	David P Schenkein	CEO	Sell	6,000	$50.01	$300,060.00	6,000
10/27/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$48.94	$122,545.76	108,405
10/5/2016	Scott Biller	Insider	Sell	5,000	$55.00	$275,000.00	48,270
9/28/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$54.00	$33,858.00	109,659
9/27/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$54.15	$33,952.05	109,659
9/20/2016	Scott Biller	Insider	Sell	5,000	$50.00	$250,000.00	48,270
8/30/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$36.81	$23,079.87	110,913
8/29/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$37.81	$23,706.87	110,913
7/26/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$42.80	$107,171.20	112,167
7/25/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$41.85	$26,239.95	112,167
6/28/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$41.88	$104,867.52	125,921
6/27/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$40.37	$25,311.99	125,921
6/8/2016	Scott Biller	Insider	Sell	27,500	$65.00	$1,787,500.00	81,376
5/26/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$51.69	$129,431.76	127,175
4/26/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$53.44	$133,813.76	128,429
4/25/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$55.00	$34,485.00	128,429
3/30/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$37.19	$93,123.76	129,683
2/26/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$37.90	$94,901.60	131,086
1/29/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$42.93	$107,496.72	131,713
12/29/2015	Lewis Clayton Jr. Cantley	Director	Sell	10,664	$64.93	$692,413.52	132,967
12/15/2015	John Duncan Higgons	COO	Sell	20,000	$50.09	$1,001,800.00	61,835
11/17/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,408	$59.83	$562,880.64	138,299
11/16/2015	John Duncan Higgons	COO	Sell	20,000	$61.51	$1,230,200.00	81,835
11/2/2015	Scott Biller	insider	Sell	5,500	$77.12	$424,160.00	34,070
10/23/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$61.16	$593,496.64	143,002
10/15/2015	John Duncan Higgons	COO	Sell	20,000	$71.04	$1,420,800.00	81,835
9/30/2015	Scott Biller	insider	Sell	5,500	$70.44	$387,420.00	34,070
9/25/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$83.25	$807,858.00	147,854
9/24/2015	Glenn Goddard	SVP	Sell	6,000	$85.97	$515,820.00
9/15/2015	John Duncan Higgons	COO	Sell	20,000	$91.11	$1,822,200.00	141,835
8/18/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$94.94	$921,297.76
8/17/2015	John Duncan Higgons	COO	Sell	20,000	$92.24	$1,844,800.00	131,835
7/23/2015	Glenn Goddard	SVP	Sell	7,000	$120.45	$843,150.00
7/20/2015	Scott Biller	Insider	Sell	5,500	$113.87	$626,285.00
7/17/2015	Glenn Goddard	SVP	Sell	13,000	$113.71	$1,478,230.00
7/16/2015	John Duncan Higgons	COO	Sell	20,000	$114.02	$2,280,400.00
7/16/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$114.28	$1,108,973.12
6/25/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$105.13	$1,020,181.52
6/15/2015	John Duncan Higgons	COO	Sell	7,000	$105.23	$736,610.00
6/8/2015	Scott Biller	Insider	Sell	5,500	$121.85	$670,175.00
6/1/2015	Christopher Bowden	Insider	Sell	5,000	$120.67	$603,350.00
6/1/2015	David P Schenkein	CEO	Sell	13,000	$120.67	$1,568,710.00
5/27/2015	David P Schenkein	CEO	Sell	8,929	$120.05	$1,071,926.45
5/27/2015	Glenn Goddard	SVP	Sell	2,171	$120.05	$260,628.55
5/20/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$116.64	$1,131,874.56
5/15/2015	John Duncan Higgons	COO	Sell	7,417	$112.89	$837,305.13
5/12/2015	David P Schenkein	CEO	Sell	5,200	$110.02	$572,104.00
5/8/2015	David P Schenkein	CEO	Sell	3,900	$101.32	$395,148.00
5/7/2015	Scott Biller	Insider	Sell	5,500	$96.32	$529,760.00
4/24/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$105.15	$1,020,375.60
4/15/2015	John Duncan Higgons	COO	Sell	6,583	$99.54	$655,271.82
4/13/2015	David P Schenkein	CEO	Sell	3,900	$100.03	$390,117.00
4/8/2015	Scott Biller	Insider	Sell	5,500	$97.64	$537,020.00
4/1/2015	David P Schenkein	CEO	Sell	3,900	$92.54	$360,906.00
3/27/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$93.58	$908,100.32
3/16/2015	Glenn Goddard	SVP	Sell	10,000	$106.24	$1,062,400.00
3/16/2015	John Duncan Higgons	COO	Sell	7,000	$106.24	$743,680.00
3/16/2015	Scott Biller	Insider	Sell	5,500	$106.81	$587,455.00
3/2/2015	David P Schenkein	CEO	Sell	7,800	$107.05	$834,990.00
2/13/2015	David P Schenkein	CEO	Sell	1,471	$120.22	$176,843.62
2/13/2015	Glenn Goddard	SVP	Sell	1,316	$120.31	$158,327.96
2/11/2015	Glenn Goddard	SVP	Sell	16,513	$107.12	$1,768,872.56
2/9/2015	Glenn Goddard	SVP	Sell	15,000	$105.81	$1,587,150.00
2/2/2015	David P Schenkein	CEO	Sell	10,400	$114.31	$1,188,824.00
1/2/2015	David P Schenkein	CEO	Sell	13,000	$110.08	$1,431,040.00
1/2/2015	John Duncan Higgons	COO	Sell	12,000	$110.08	$1,320,960.00
1/2/2015	Scott Biller	Insider	Sell	4,500	$110.08	$495,360.00
12/16/2014	Celgene European Investment Co	Major Shareholder	Buy	228,645	$110.75	$25,322,433.75
12/16/2014	John Maraganore	Director	Buy	1,806	$110.75	$200,014.50
12/1/2014	David P Schenkein	CEO	Sell	13,000	$97.03	$1,261,390.00
12/1/2014	John Duncan Higgons	COO	Sell	12,000	$97.03	$1,164,360.00
12/1/2014	Scott Biller	Insider	Sell	4,500	$97.03	$436,635.00
11/3/2014	Glenn Goddard	SVP	Sell	2,000	$81.71	$163,420.00
11/3/2014	John Duncan Higgons	COO	Sell	13,000	$81.71	$1,062,230.00
11/3/2014	Scott Biller	Insider	Sell	4,500	$81.71	$367,695.00
10/1/2014	Glenn Goddard	SVP	Sell	1,500	$60.07	$90,105.00
10/1/2014	John Duncan Higgons	COO	Sell	13,000	$60.07	$780,910.00
10/1/2014	Scott Biller	Insider	Sell	4,500	$60.07	$270,315.00
9/26/2014	David P Schenkein	CEO	Sell	60,000	$62.68	$3,760,800.00
9/26/2014	Glenn Goddard	SVP	Sell	17,500	$56.53	$989,275.00
9/19/2014	Scott Biller	Insider	Sell	37,996	$50.45	$1,916,898.20
9/2/2014	Glenn Goddard	SVP	Sell	10,000	$46.30	$463,000.00
9/2/2014	John Duncan Higgons	COO	Sell	13,000	$46.30	$601,900.00
9/2/2014	Scott Biller	Insider	Sell	4,500	$46.30	$208,350.00
8/26/2014	John Duncan Higgons	COO	Sell	5,000	$45.05	$225,250.00
8/11/2014	David P Schenkein	CEO	Sell	4,530	$40.17	$181,970.10
7/1/2014	David P Schenkein	CEO	Sell	13,000	$46.52	$604,760.00
7/1/2014	Glenn Goddard	SVP	Sell	3,500	$46.52	$162,820.00
7/1/2014	John Duncan Higgons	COO	Sell	12,000	$46.52	$558,240.00
7/1/2014	Scott Biller	Insider	Sell	4,500	$46.52	$209,340.00
6/23/2014	John Maraganore	Director	Buy	2,300	$43.98	$101,154.00
6/20/2014	Scott Biller	Insider	Sell	2,004	$50.05	$100,300.20
6/13/2014	John Duncan Higgons	COO	Sell	5,000	$45.27	$226,350.00
6/3/2014	John Duncan Higgons	COO	Sell	7,000	$34.47	$241,290.00
5/6/2014	John Duncan Higgons	COO	Sell	5,000	$45.73	$228,650.00	200,090
5/1/2014	Glenn Goddard	SVP	Sell	2,000	$42.39	$84,780.00
5/1/2014	John Duncan Higgons	COO	Sell	7,000	$42.39	$296,730.00	205,090
5/1/2014	Scott Biller	Insider	Sell	4,500	$42.39	$190,755.00	30,000
4/29/2014	Celgene European Investment Co	major shareholder	Buy	294,800	$44.00	$12,971,200.00
4/29/2014	John Maraganore	Director	Buy	2,250	$44.00	$99,000.00	46,583
4/7/2014	Glenn Goddard	SVP	Sell	2,000	$45.17	$90,340.00
4/7/2014	John Duncan Higgons	COO	Sell	3,000	$45.17	$135,510.00	209,090
4/1/2014	Glenn Goddard	SVP	Sell	4,000	$38.08	$152,320.00
4/1/2014	John Duncan Higgons	COO	Sell	12,000	$38.08	$456,960.00	209,090
4/1/2014	Scott Biller	Insider	Sell	4,500	$38.08	$171,360.00	30,000
3/7/2014	Glenn Goddard	SVP	Sell	17,468	$42.11	$735,577.48
3/7/2014	John Duncan Higgons	COO	Sell	14,646	$41.41	$606,490.86	109,090
3/3/2014	John Duncan Higgons	COO	Sell	8,000	$29.85	$238,800.00	109,090
3/3/2014	Scott Biller	Insider	Sell	6,000	$29.85	$179,100.00
2/10/2014	Glenn Goddard	SVP	Sell	6,000	$30.44	$182,640.00
1/27/2014	Glenn Goddard	SVP	Sell	7,000	$26.29	$184,030.00
1/21/2014	Glenn Goddard	SVP	Sell	10,000	$34.71	$347,100.00
7/29/2013	Celgene European Investment Co	Major Shareholder	Buy	708,333	$18.00	$12,749,994.00

(Data available from 1/1/2013 forward)

Agios Pharmaceuticals (NASDAQ AGIO) News Headlines

Source:

Date	Headline
	Heard in the halls of biotech: I’ll meet you in the Valium room. www.msn.com - April 21 at 8:18 AM
	Agios' Leukemia Drug Bodes Well for Growth & Strong Pipeline finance.yahoo.com - April 18 at 5:46 PM
	Cann Reaffirms "Hold" Rating for Agios Pharmaceuticals (AGIO) www.americanbankingnews.com - April 17 at 11:37 AM
	Christopher Bowden Sells 2,000 Shares of Agios Pharmaceuticals (AGIO) Stock www.americanbankingnews.com - April 16 at 4:27 PM
	Agios Pharmaceuticals' (AGIO) Hold Rating Reaffirmed at Janney Montgomery Scott www.americanbankingnews.com - April 14 at 10:05 AM
	Agios Pharmaceuticals (AGIO) Upgraded by Leerink Swann to "Outperform" www.americanbankingnews.com - April 14 at 10:05 AM
	$13.59 Million in Sales Expected for Agios Pharmaceuticals (AGIO) This Quarter www.americanbankingnews.com - April 14 at 4:21 AM
	Agios Pharmaceuticals (AGIO) Expected to Announce Earnings of -$1.60 Per Share www.americanbankingnews.com - April 12 at 9:07 AM
	Agios Pharmaceuticals (AGIO) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - April 11 at 10:42 PM
	Credit Suisse Group Reiterates "$95.00" Price Target for Agios Pharmaceuticals (AGIO) www.americanbankingnews.com - April 11 at 9:21 AM
	Needham & Company LLC Raises Agios Pharmaceuticals (AGIO) Price Target to $72.00 www.americanbankingnews.com - April 10 at 11:38 PM
	Scott Biller Sells 3,000 Shares of Agios Pharmaceuticals (AGIO) Stock www.americanbankingnews.com - April 9 at 7:19 PM
	Why Alcoa, Merck, and Agios Pharmaceuticals Jumped Today finance.yahoo.com - April 9 at 5:23 PM
	ASLAN Pharmaceuticals Files For $86 Million US IPO seekingalpha.com - April 7 at 8:22 AM
	David P. Schenkein Sells 13,000 Shares of Agios Pharmaceuticals (AGIO) Stock www.americanbankingnews.com - April 4 at 10:40 PM
	Agios Pharmaceuticals (AGIO) Rating Increased to Buy at ValuEngine www.americanbankingnews.com - April 3 at 8:10 PM
	Analysts’ Ratings for Athenex and Its Peers in March finance.yahoo.com - April 2 at 8:37 AM
	Agios Pharmaceuticals (AGIO) Given New $66.00 Price Target at Credit Suisse Group www.americanbankingnews.com - April 1 at 10:52 PM
	ValuEngine Upgrades Agios Pharmaceuticals (AGIO) to "Hold" www.americanbankingnews.com - March 31 at 3:48 PM
	Oppenheimer Analysts Give Agios Pharmaceuticals (AGIO) a $83.00 Price Target www.americanbankingnews.com - March 31 at 2:06 PM
	Agios Pharmaceuticals (AGIO) Receives Average Rating of "Buy" from Analysts www.americanbankingnews.com - March 31 at 11:34 AM
	How Analysts View Agios Pharmaceuticals and Peers in March 2018 finance.yahoo.com - March 30 at 8:20 AM
	An Insight into Agios Pharmaceuticals’ Product Pipeline finance.yahoo.com - March 30 at 8:20 AM
	Exploring Agios Pharmaceuticals’ Cash Flows finance.yahoo.com - March 30 at 8:20 AM
	Agios Pharmaceuticals (AGIO) Upgraded to Buy by Zacks Investment Research www.americanbankingnews.com - March 29 at 11:18 PM
	Agios Pharmaceuticals (AGIO) Stock Rating Upgraded by Zacks Investment Research www.americanbankingnews.com - March 28 at 12:58 PM
	Agios Pharmaceuticals (AGIO) Raised to "Buy" at BidaskClub www.americanbankingnews.com - March 28 at 11:57 AM
	Brokerages Expect Agios Pharmaceuticals (AGIO) Will Announce Quarterly Sales of $13.59 Million www.americanbankingnews.com - March 28 at 8:09 AM
	Insider Selling: Agios Pharmaceuticals Inc (AGIO) Insider Sells 2,050 Shares of Stock www.americanbankingnews.com - March 26 at 4:10 PM
	Agios Pharmaceuticals (AGIO) Upgraded to Hold at ValuEngine www.americanbankingnews.com - March 25 at 9:16 PM
	Juno Therapeutics And Agios: Two Really Big Fish That Got Away www.forbes.com - March 24 at 8:48 AM
	Kaye I. Foster-Cheek Sells 6,800 Shares of Agios Pharmaceuticals Inc (AGIO) Stock www.americanbankingnews.com - March 21 at 4:08 PM
	Wired News – Agios Pharmaceuticals Doses First Patient in AG-270 Phase-1 Dose-Escalation Trial in MTAP-Deleted Tumors finance.yahoo.com - March 21 at 8:45 AM
	Agios Pharmaceuticals Inc (AGIO) Director David Scadden Purchases 200 Shares www.americanbankingnews.com - March 20 at 8:32 PM
	BRIEF-Agios Says First Patient Dosed In Lymphoma Study www.reuters.com - March 19 at 5:19 PM
	Agios Announces First Patient Dosed with MAT2A Inhibitor AG-270 in Phase 1 Study in Patients with Advanced Solid ... - GlobeNewswire (press release) globenewswire.com - March 19 at 8:20 AM
	Agios Pharma (AGIO) Reports 1st Patient Dosed with MAT2A Inhibitor AG-270 in Phase 1 Study - StreetInsider.com www.streetinsider.com - March 19 at 8:20 AM
	Agios Announces First Patient Dosed with MAT2A Inhibitor AG-270 in Phase 1 Study in Patients with Advanced Solid Tumors or Lymphoma with an MTAP Deletion finance.yahoo.com - March 19 at 8:20 AM
	What's Happening with These Biotech Stocks? -- Aeterna Zentaris, Affimed, Agenus, and Agios Pharma - PR Newswire (press release) www.prnewswire.com - March 13 at 8:23 AM
	Zacks: Analysts Anticipate Agios Pharmaceuticals Inc (AGIO) Will Post Quarterly Sales of $13.42 Million www.americanbankingnews.com - March 11 at 9:46 AM
	-$1.60 EPS Expected for Agios Pharmaceuticals Inc (AGIO) This Quarter www.americanbankingnews.com - March 9 at 1:27 AM
	Agios Pharmaceuticals Inc (AGIO) Insider Sells $249,240.00 in Stock www.americanbankingnews.com - March 7 at 6:50 PM
	Agios Pharmaceuticals Inc (AGIO) Receives Average Rating of "Buy" from Analysts www.americanbankingnews.com - March 6 at 11:44 AM
	Agios Pharmaceuticals Inc (AGIO) CEO David P. Schenkein Sells 13,000 Shares www.americanbankingnews.com - March 5 at 6:40 PM
	Agios Pharmaceuticals Inc (AGIO) Stake Boosted by UBS Asset Management Americas Inc. www.americanbankingnews.com - March 4 at 10:46 AM
	Agios Pharmaceuticals Inc (AGIO) Stake Boosted by Swiss National Bank www.americanbankingnews.com - March 4 at 8:22 AM
	Agios Pharmaceuticals (AGIO) Upgraded at BidaskClub www.americanbankingnews.com - March 3 at 6:10 PM
	Eaton Vance Management Acquires 43,741 Shares of Agios Pharmaceuticals Inc (AGIO) www.americanbankingnews.com - March 2 at 12:05 PM
	Agios Pharmaceuticals Inc (AGIO) Insider Steven L. Hoerter Sells 2,050 Shares www.americanbankingnews.com - February 26 at 6:50 PM
	Brown Advisory Inc. Has $17.41 Million Holdings in Agios Pharmaceuticals Inc (AGIO) www.americanbankingnews.com - February 25 at 4:36 AM

Agios Pharmaceuticals (NASDAQ:AGIO) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Agios Pharmaceuticals (NASDAQ:AGIO) Income Statement, Balance Sheet and Cash Flow Statement

Agios Pharmaceuticals (NASDAQ AGIO) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff